Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform Read More Jan 8, 2026
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program Read More Jan 6, 2026
Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1) Read More Dec 3, 2025
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update Read More Nov 12, 2025
Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors Read More Nov 12, 2025
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update Read More Nov 7, 2025
